证券代码：600587 证券简称：新华医疗 公告编号：临 2025-023 山东新华医疗器械股份有限公司 关于参加 2025 年山东辖区上市公司投资者 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东新华医疗器械股份有限公司（以下简 称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联 合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相关事项 公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP, 参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公司 高管将在线就公司 2024 年度和 2025 年第一季度业绩、公司治理、发展战略、经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 特此公告！ 山东新华医疗器械股份有限公司董事会 2025 年 5 月 1 ...

Investment Rating - The industry investment rating is "Positive" [1] Core Viewpoints - The medical device sector is currently at a valuation bottom, with a significant acceleration in domestic substitution expected. The recovery of hospital procurement and the completion of centralized procurement are anticipated to enhance the performance of domestic companies [3][41] - The report highlights the potential for substantial growth in high-value consumables, particularly in areas such as electrophysiology, orthopedics, coronary intervention, and artificial lenses, as companies emerge from the impacts of centralized procurement and inventory adjustments [3][41] - The medical equipment segment is expected to see a recovery in performance in the second half of 2025, driven by the resumption of hospital procurement and overseas expansion [3][44] - The home medical device market is projected to regain growth due to a recovering consumer environment and ongoing new product investments [3][54] Summary by Sections Valuation - The medical device sector is currently at historical low valuations, with medical equipment at a PE of 32x, medical consumables at 30x, and in vitro diagnostics (IVD) at 24x as of April 30, 2025 [9] Growth Potential - Demand for low-value and high-value consumables remains stable, with expected positive revenue growth in 2024. However, other segments like medical equipment and IVD are experiencing revenue and profit declines due to procurement impacts [12][13] Profitability - Profitability has declined across most segments except for low-value consumables, with net profit margins decreasing in 2024. The report notes that the recovery of net profit margins is expected in 2025 as expense ratios decrease [25][31] Operational Efficiency - High-value consumables have achieved the highest accounts receivable turnover since 2020, indicating improved operational efficiency as companies adjust to the impacts of centralized procurement [32] Domestic Substitution - The report emphasizes the acceleration of domestic substitution in high-end medical devices due to increased tariffs and competitive product capabilities. Companies with low domestic production rates and significant import substitution potential are recommended [39][41] Investment Recommendations - The report suggests investing in high-value consumables companies that are entering a growth phase post-centralized procurement, as well as medical equipment and home medical device companies that are expected to see steady revenue growth [54]

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

Core Insights - The total revenue of 33 A-share listed companies in Zibo for 2024 is approximately 147.77 billion yuan, with 23 companies showing revenue growth compared to the previous year [1][2] - The total net profit for these companies is around 6.66 billion yuan, with 19 companies experiencing a year-on-year increase in net profit [1][8] Revenue Performance - 23 companies achieved positive revenue growth, while 10 companies reported declines [2] - Three companies surpassed the 10 billion yuan revenue mark: Qixiang Tengda (25.22 billion yuan), Bohui Paper (18.93 billion yuan), and Xinhua Medical (10.02 billion yuan) [2][4] - Qixiang Tengda remains the revenue leader despite a 6.31% decline in revenue [4] - Bohui Paper produced 4.53 million tons of paper, achieving a revenue of 18.93 billion yuan, a 1.27% increase [4] - Xinhua Medical's revenue increased slightly by 0.09%, with significant growth in its pharmaceutical equipment segment [4][5] Profitability Analysis - The total net profit of 33 companies is approximately 6.66 billion yuan, with notable profit leaders being Yingke Medical (1.47 billion yuan), Shandong Yaobang (943 million yuan), and Xinhua Medical (692 million yuan) [8][9] - Yingke Medical's net profit surged by 282.63%, marking it as the most profitable company [9][10] - 19 companies reported an increase in net profit, while 14 companies experienced declines [8][12] - Five companies saw net profit declines exceeding 50%, with Yahua Electronics reporting a significant loss of 26 million yuan [12][13] Notable Companies - Yingke Medical's production capacity utilization reached 100%, with a recovery in sales prices compared to 2023 [10] - Bohui Paper's strong production capacity contributed to its stable revenue growth [4] - Xinhua Medical is expanding its international presence with five overseas sales centers [5] - Blue Sail Medical, despite a revenue increase of 26.91%, reported a loss of 446 million yuan [16]

Group 1: Macro Insights - The Federal Reserve maintained interest rates and emphasized increasing uncertainty, with market expectations for rate cuts in June and July at 20% and 80% respectively, and a total of three cuts expected for the year [4] - The current economic environment presents a dual challenge of stagnation versus inflation, with short-term liquidity crises and long-term recession concerns [4] Group 2: TMT Sector Analysis - The TMT sector shows high levels of crowding, suggesting a cautious approach as the market may continue to favor lower-performing sectors [5] - The industry rotation model indicates that cyclical sectors like non-ferrous metals, steel, food and beverage, and building materials are in a strong trend with low crowding, while TMT remains crowded [5] Group 3: Coal Industry Overview - As of Q1 2025, the coal industry is experiencing a significant downturn, with coal prices returning to levels seen in early 2021, and the average price of Q5500 coal at 657 RMB/ton, down 111 RMB/ton since the beginning of the year [14][15] - The total profit of large coal enterprises in Q1 2025 was 803.8 billion RMB, a year-on-year decrease of 47.7%, with over half of coal companies reporting losses [17] - Major coal companies like China Shenhua and Shaanxi Coal have substantial cash reserves, indicating strong dividend-paying capabilities despite the industry's challenges [7][9] Group 4: Media Sector Performance - The media sector showed a significant recovery in Q1 2025, with notable performances in gaming and cinema, and a positive outlook for the year [22] - The film industry, particularly, is expected to benefit from a strong lineup of releases, although some major films underperformed [26] Group 5: Home Appliance and Electric Vehicle Industry - The electric two-wheeler market is expected to see growth driven by brand and channel advantages, with a projected increase in demand primarily from replacement sales [22][23] - The home appliance sector is focusing on expanding smart product offerings and enhancing international market presence, with significant revenue growth reported in smart home products [28] Group 6: Medical and Biopharmaceutical Sector - Companies like Xinhua Medical and Anjisi are showing steady growth, with Xinhua Medical reporting a slight increase in revenue and profit, while Anjisi's revenue grew by 25.14% in 2024 [36][38] - The biopharmaceutical sector is focusing on diversifying revenue streams and expanding into international markets, with significant growth expected in the coming years [35][40] Group 7: Investment Recommendations - Key recommendations include investing in leading coal enterprises like China Shenhua and Zhongmei Energy, as well as companies showing potential for recovery like Qinfa [19][20] - In the media sector, companies with strong content pipelines and market positions are recommended for investment [26]

Company Overview - Shandong Xinhua Medical Equipment Co., Ltd. specializes in the manufacturing and sales of medical devices and pharmaceutical equipment, providing compatible medical services and medical commerce [2] - The company is a leading entity in the Chinese medical device industry, holding several key positions in various associations, including the China Medical Device Industry Association and the China Pharmaceutical Equipment Industry Association [2] - Xinhua Medical has developed several innovative products, including the world's first peracetic acid low-temperature sterilizer and the first high-energy medical linear accelerator in China [2] Financial Performance - For Q1 2025, the company reported a revenue of 2.308 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 160 million yuan, down 23.97% compared to the previous year [3] - The company's gross profit margin stands at 23.79% [3] Market Position - As of May 7, the company's stock closed at 14.95 yuan, with a rolling price-to-earnings (PE) ratio of 14.15 times, and a total market capitalization of 9.07 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 49.02 times, with a median of 36.25 times, placing Xinhua Medical at the 33rd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xinhua Medical reached 38,959, an increase of 5,308 from the previous count, with an average holding value of 352,800 yuan per shareholder and an average holding of 27,600 shares [1]

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 近日， 新华医疗 发布了2024年年报和2025年一季报。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | --- | --- | --- | --- | --- | | | | | 期增减(%) | | | 营业收入 | 10,020,618,625.09 | 10,011,868,423.40 | 0.09 | 9,281,768,657.18 | | 归属于上市公司股东的净利润 | 691,609,558.03 | 653,997,275.95 | 5.75 | 500,072,195.90 | | 归属于上市公司股东的扣除非经 常性损益的净利润 | 623,195,651.23 | 619,448,862.20 | 0.60 | 502,815,889.23 | | 经营活动产生的现金流量净额 | 450,733,485.54 | 1,030,114,479.17 | -56.24 | 388,048,566.87 | | | 2024年末 | 2023年末 | 本期末比上年 ...

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

2024 年度独立董事述职报告 作为山东新华医疗器械股份有限公司(以下简称"公司")的独立董事,根 据《公司法》、《上市公司独立董事管理办法》、《关于在上市公司建立独立董事制 度的指导意见》、《上海证券交易所股票上市规则》、《独立董事工作制度》等相关 法律法规和规章制度的规定和要求,在 2024年的工作中,勤勉、尽责、忠实履 行职务,积极出席相关会议,认真审议董事会各项议案,对公司相关事项发表独 立意见,切实维护了公司和股东尤其是社会公众股股东的利益。现将 2024 年度 我在履行独立董事职责方面的情况述职如下: 一、独立董事的基本情况 黎元:1995年至今任职于复旦大学附属华山医院;2020年11月至 2022年 8 月任山东未名生物医药股份有限公司独立董事;2021年8月至今任公司独立董 事。 山东新华医疗器械股份有限公司 | 专门委员会类别 | 报告期内召 | 应参加会议次 | 参加次数 | 委托出席次 | | --- | --- | --- | --- | --- | | | 开次数 | 数 | | 数 | | 薪酬与考核委员会 | | | | | | 审计委员会 | | | | | | 战略委员会 ...

（1）公司及控股子公司淄博众生医药有限公司（以下简称"众生医药"） 与公司控股股东山东颐养健康产业发展集团有限公司（以下简称"山东健康"） 权属医疗机构及子公司之间的关联交易,众生医药向山东健康权属医疗机构及子 公司配送药品、材料均依照市场价格执行，有利于扩大销售规模，增加众生医药 的议价能力, 不存在损害公司及其他股东利益的情形。 （2）公司与联营企业山东高新医疗器械创新中心有限公司（以下简称"高 新创新中心"）全资子公司深圳华创智新医疗科技有限公司（以下简称"华创医 疗"）的关联交易，主要是公司向华创医疗销售医疗器械、耗材，销售价格依照 市场价格执行，有利于公司延长产业链。该等关联交易定价公允，不存在损害公 司及其他股东利益的情形。 山东新华医疗器械股份有限公司独立董事 关于第十一届董事会第十八次会议相关议案的事前认可意见 根据《关于上市公司建立独立董事制度的指导意见》、《上市公司治理准则》 和《上海证券交易所股票上市规则》以及《公司章程》等有关规定，我们作为公 司的独立董事，在认真审阅有关资料和听取相关人员汇报的基础上，对山东新华 医疗器械股份有限公司（以下简称"新华医疗"或"公司"）第十一届董事会第 ...